Home > Product > APIs > Ganirelix



Price Inquiry
Antagon; orgalutran; RS 26306; RS-26306; RS26306; Ganirelixum; LS-181948; LS181948; LS 181948
Ac-DNal-DCpa-DPal-Ser-Tyr-DHar(Et2)-Leu-Har(Et2)-Pro-DAla -NH2
Molecular Formula
Long-term Storage Conditions
Ganirelix is primarily used in assisted reproduction to control ovulation.
Ganirelix acetate (or diacetate) is an injectable competitive gonadotropin-releasing hormone antagonist (GnRH antagonist). It works by blocking the action of GnRH upon the pituitary, thus rapidly suppressing the production and action of LH and FSH.
Areas of Interest
Hormonal therapy
  • Background
  • Related Products
  • References

Ganirelix Acetate is the acetate salt form of ganirelix, a synthetic decapeptide with high antagonistic activity against naturally occurring gonadotropin-releasing hormone (GnRH). Ganirelix directly competes with the GnRH for receptor binding in the anterior pituitary gland, thus induces a rapid and reversible suppression of the release of follicle stimulating hormone (FSH) and luteinizing hormone (LH). This agent is used for the inhibition of premature LH surges in women undergoing controlled ovarian hyperstimulation, and in combination with other hormones for retrieval of the mature follicles for in-vitro fertilization.

CAS: 34973-08-5
Sequence: Pyr-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2 acetate salt
M.W: 1242.36
Molecular Formula: C55H75N17O13.C2H4O2
CAS: 33515-09-2 (net)
Sequence: Pyr-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2 hydrochloride salt
M.W: 1182.31
Molecular Formula: C55H75N17O13
CAS: 83930-13-6 (net)
Sequence: H-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu-NH2 acetate salt
M.W: 5039.72
Molecular Formula: C215H358N72O66S
CAS: 76712-82-8 (net)
Sequence: Pyr-His-Trp-Ser-Tyr-D-His(Bzl)-Leu-Arg-Pro-NHEt acetate salt
M.W: 1323.5
Molecular Formula: C66H86N18O12
CAS: 63968-82-1
Sequence: Asp-Val-Pro-Lys-Ser-Asp-Gln-Phe-Val-Gly-Leu-Met-NH2
M.W: 1334.54
Molecular Formula: C59H95N15O18S

Use of GnRH antagonists in patients with an a priori poor IVF prognosis results in predictably poor outcomes. Patients without factors predicting poor outcome have acceptable PRs. The pattern of E2 rise immediately after initiation of GnRH antagonists does not predict cycle outcome. Oral contraceptives can be successfully used to schedule antagonist-based IVF cycles but might increase the risk of cycle cancellation in some patient populations.

Shapiro, D. B., Mitchell-Leef, D., Carter, M., & Nagy, Z. P. (2005). Ganirelix acetate use in normal-and poor-prognosis patients and the impact of estradiol patterns. Fertility and sterility, 83(3), 666-670.

Elevated estradiol (E(2)) levels predispose to development of ovarian hyperstimulation syndrome (OHSS). Since GnRH antagonist is associated with a reduction in E(2) levels, we hypothesized that GnRH-antagonist treatment of women down-regulated with GnRH agonist who are at risk of OHSS might reduce E(2) levels and avoid cycle cancellation.

Gustofson, R. L., Segars, J. H., & Larsen, F. W. (2006). Ganirelix acetate causes a rapid reduction in estradiol levels without adversely affecting oocyte maturation in women pretreated with leuprolide acetate who are at risk of ovarian hyperstimulation syndrome. Human Reproduction, 21(11), 2830-2837.

Ganirelix is effective, safe, and well tolerated. Compared with leuprolide acetate, ganirelix therapy has a shorter duration and fewer injections but produces a similar pregnancy rate.

Fluker, M., Grifo, J., Leader, A., Levy, M., Meldrum, D., Muasher, S. J., ... & Shapiro, D. B. (2001). Efficacy and safety of ganirelix acetate versus leuprolide acetate in women undergoing controlled ovarian hyperstimulation. Fertility and sterility, 75(1), 38-45.

Online Inquiry

Name (First Last) *
Email *
Phone *
Service & Products of Interest *
Services Required and Project Description
Verification code *Please enter the code "peptides"
Home | Site Map | Contact Us | Resources
Copyright © 2008 - Creative Peptides. All rights reserved.